Benefit Profile of Thrombomodulin Alfa Combined with Antithrombin Concentrate in Patients with Sepsis-Induced Disseminated Intravascular Coagulation

Overview

Journal Clin Appl Thromb Hemost

Publisher Sage Publications

Specialty Cardiology & Vascular Diseases

Date 2022 Feb 15

PMID 35166576

Authors

Atsushi Murao

Takayuki Kato

Tetsunobu Yamane

Goichi Honda

Yutaka Eguchi

Affiliations

Soon will be listed here.

Abstract

Thrombomodulin alfa (TM-α, recombinant human soluble thrombomodulin) and antithrombin (AT) concentrate are anticoagulant agents for the treatment of disseminated intravascular coagulation (DIC). A post hoc analysis using data from 1198 patients with infection-induced DIC from the post-marketing surveillance of TM-α was conducted. To identify subgroups that benefit from combination therapy, the patients were a priori stratified into four groups by a platelet (Plt) count of 50 × 10/μL and plasma AT level of 50% (groups 1, 2, 3, and 4, with high Plt/high AT, high Plt/low AT, low Plt/high AT, and low Plt/low AT, respectively). Kaplan-Meier survival analysis showed significantly worse survival in groups 2 and 4 had than in group 1 (p = 0.0480, p < 0.0001, respectively), and multivariate analysis showed that concomitant AT concentrate was independently correlated with reduced 28-day mortality only in group 4 (hazard ratio 0.6193; 95% confidence interval, 0.3912-0.9805). The adverse drug reactions (ADRs) and bleeding ADRs were not different among the groups. Patients with both severe thrombocytopenia and AT deficiency are candidates for combined anticoagulant therapy with TM-α and AT concentrate.

Citing Articles

Clinical practice guidelines for management of disseminated intravascular coagulation in Japan 2024: significance of guidelines developed for each underlying disease.

Asakura H Int J Hematol. 2025; .

PMID: 39954183 DOI: 10.1007/s12185-025-03928-y.

Effects of combination therapy of antithrombin and thrombomodulin for sepsis-associated disseminated intravascular coagulation: a systematic review and meta-analysis.

Totoki T, Makino Y, Yamakawa K, Koami H, Wada T, Ito T Thromb J. 2024; 22(1):10.

PMID: 38225597 PMC: 10788990. DOI: 10.1186/s12959-023-00579-z.

Comparison of the prognostic value of four different critical illness scores in patients with sepsis-induced coagulopathy.

Wang C, Ma L, Zhang W Open Life Sci. 2023; 18(1):20220659.

PMID: 37588996 PMC: 10426719. DOI: 10.1515/biol-2022-0659.

The pathophysiology, diagnosis, and management of sepsis-associated disseminated intravascular coagulation.

Iba T, Helms J, Connors J, Levy J J Intensive Care. 2023; 11(1):24.

PMID: 37221630 PMC: 10202753. DOI: 10.1186/s40560-023-00672-5.

Endothelial dysfunction and immunothrombosis in sepsis.

Maneta E, Aivalioti E, Tual-Chalot S, Emini Veseli B, Gatsiou A, Stamatelopoulos K Front Immunol. 2023; 14:1144229.

PMID: 37081895 PMC: 10110956. DOI: 10.3389/fimmu.2023.1144229.

References

Iba T, Nakarai E, Takayama T, Nakajima K, Sasaoka T, Ohno Y . Combination effect of antithrombin and recombinant human soluble thrombomodulin in a lipopolysaccharide induced rat sepsis model. Crit Care. 2009; 13(6):R203. PMC: 2811901. DOI: 10.1186/cc8210. View

Yasuda N, Goto K, Ohchi Y, Abe T, Koga H, Kitano T . The efficacy and safety of antithrombin and recombinant human thrombomodulin combination therapy in patients with severe sepsis and disseminated intravascular coagulation. J Crit Care. 2016; 36:29-34. DOI: 10.1016/j.jcrc.2016.06.008. View

Engelmann B, Massberg S . Thrombosis as an intravascular effector of innate immunity. Nat Rev Immunol. 2012; 13(1):34-45. DOI: 10.1038/nri3345. View

Umemura Y, Yamakawa K, Hayakawa M, Kudo D, Fujimi S . Concomitant Versus Individual Administration of Antithrombin and Thrombomodulin for Sepsis-Induced Disseminated Intravascular Coagulation: A Nationwide Japanese Registry Study. Clin Appl Thromb Hemost. 2018; 24(5):734-740. PMC: 6714866. DOI: 10.1177/1076029618755948. View

Mazzeffi M, Chow J, Amoroso A, Tanaka K . Revisiting the Protein C Pathway: An Opportunity for Adjunctive Intervention in COVID-19?. Anesth Analg. 2020; 131(3):690-693. PMC: 7302080. DOI: 10.1213/ANE.0000000000005059. View

Mimuro J, Takahashi H, Kitajima I, Tsuji H, Eguchi Y, Matsushita T . Impact of recombinant soluble thrombomodulin (thrombomodulin alfa) on disseminated intravascular coagulation. Thromb Res. 2013; 131(5):436-43. DOI: 10.1016/j.thromres.2013.03.008. View

Ito T, Kakuuchi M, Maruyama I . Endotheliopathy in septic conditions: mechanistic insight into intravascular coagulation. Crit Care. 2021; 25(1):95. PMC: 7938685. DOI: 10.1186/s13054-021-03524-6. View

Levi M, van der Poll T . The role of natural anticoagulants in the pathogenesis and management of systemic activation of coagulation and inflammation in critically ill patients. Semin Thromb Hemost. 2008; 34(5):459-68. DOI: 10.1055/s-0028-1092876. View

Hui P, Cook D, Lim W, Fraser G, Arnold D . The frequency and clinical significance of thrombocytopenia complicating critical illness: a systematic review. Chest. 2010; 139(2):271-278. DOI: 10.1378/chest.10-2243. View

10.

Ebina M, Fujino K, Inoue A, Ariyoshi K, Eguchi Y . Effects of Serum Albumin Levels on Antithrombin Supplementation Outcomes Among Patients With Sepsis-Associated Coagulopathy: A Retrospective Study. Clin Med Insights Blood Disord. 2019; 12:1179545X19858361. PMC: 6589945. DOI: 10.1177/1179545X19858361. View

11.

Matsubara T, Yamakawa K, Umemura Y, Gando S, Ogura H, Shiraishi A . Significance of plasma fibrinogen level and antithrombin activity in sepsis: A multicenter cohort study using a cubic spline model. Thromb Res. 2019; 181:17-23. DOI: 10.1016/j.thromres.2019.07.002. View

12.

Tsirigotis P, Chondropoulos S, Frantzeskaki F, Stamouli M, Gkirkas K, Bartzeliotou A . Thrombocytopenia in critically ill patients with severe sepsis/septic shock: Prognostic value and association with a distinct serum cytokine profile. J Crit Care. 2016; 32:9-15. DOI: 10.1016/j.jcrc.2015.11.010. View

13.

Tagami T, Matsui H, Horiguchi H, Fushimi K, Yasunaga H . Antithrombin and mortality in severe pneumonia patients with sepsis-associated disseminated intravascular coagulation: an observational nationwide study. J Thromb Haemost. 2014; 12(9):1470-9. DOI: 10.1111/jth.12643. View

14.

Asakura H, Ontachi Y, Mizutani T, Kato M, Ito T, Saito M . Decreased plasma activity of antithrombin or protein C is not due to consumption coagulopathy in septic patients with disseminated intravascular coagulation. Eur J Haematol. 2001; 67(3):170-5. DOI: 10.1034/j.1600-0609.2001.5790508.x. View

15.

Zhou H, Li Z, Liang H, Yan Z . Thrombocytopenia and platelet count recovery in patients with sepsis-3: a retrospective observational study. Platelets. 2021; 33(4):612-620. DOI: 10.1080/09537104.2021.1970124. View

16.

Chen Z, Zhang H, Qu M, Nan K, Cao H, Cata J . Review: The Emerging Role of Neutrophil Extracellular Traps in Sepsis and Sepsis-Associated Thrombosis. Front Cell Infect Microbiol. 2021; 11:653228. PMC: 8010653. DOI: 10.3389/fcimb.2021.653228. View

17.

Fourrier F, Chopin C, Goudemand J, Hendrycx S, Caron C, Rime A . Septic shock, multiple organ failure, and disseminated intravascular coagulation. Compared patterns of antithrombin III, protein C, and protein S deficiencies. Chest. 1992; 101(3):816-23. DOI: 10.1378/chest.101.3.816. View

18.

Ghimire S, Ravi S, Budhathoki R, Arjyal L, Hamal S, Bista A . Current understanding and future implications of sepsis-induced thrombocytopenia. Eur J Haematol. 2020; 106(3):301-305. DOI: 10.1111/ejh.13549. View

19.

Ito T, Thachil J, Asakura H, Levy J, Iba T . Thrombomodulin in disseminated intravascular coagulation and other critical conditions-a multi-faceted anticoagulant protein with therapeutic potential. Crit Care. 2019; 23(1):280. PMC: 6694689. DOI: 10.1186/s13054-019-2552-0. View

20.

Thiery-Antier N, Binquet C, Vinault S, Meziani F, Boisrame-Helms J, Quenot J . Is Thrombocytopenia an Early Prognostic Marker in Septic Shock?. Crit Care Med. 2015; 44(4):764-72. DOI: 10.1097/CCM.0000000000001520. View